阿尔茨海默病的临床表型:研究缩模式及其病理相关物
Niels Reijner1,2,3, I Frigerio4,5,6, M M A Bouwman4,5,6
1Department of Anatomy and Neurosciences, Amsterdam UMC, Vrije Universiteit Amsterdam, De Boelelaan 1108, Amsterdam, 1081 HZ, Netherlands. n.reijner@amsterdamumc.nl.
Alzheimer's research & therapy
|April 25, 2025
概括
阿尔茨海默病 (AD) 脑缩受粉样β (Aβ) 和神经轴突损伤的影响,不同影响典型和非典型的AD表型. 了解这些体积-病理关系可以改善在AD研究和临床环境中的MRI解释.
科学领域:
- 神经成像是一种神经成像.
- 神经病理学神经病理学
- 阿尔茨海默氏症疾病研究研究
背景情况:
- 核磁共振图像缩模式区分阿尔茨海默病 (AD) 的表型 (记忆障碍/典型与非记忆障碍/非典型).
- 这些模式对于AD诊断和临床试验结果至关重要.
- 蛋白质积累和神经退行对阿尔茨海默氏症MRI测量的影响尚未完全理解.
研究的目的:
- 为了研究典型和非典型AD的区域MRI皮质缩模式.
- 评估这些缩模式与关键神经病理标志物之间的关联:粉样β (Aβ),酸化 (pTau),神经轴突退化和微血管恶化.
主要方法:
- 利用了33名AD (17例典型,16例非典型) 和16例对照大脑捐赠者的死后现场3DT1和3T-MRI数据.
- 收集死亡前的MRI扫描,如果有,进行区域体积分析,使用基于地图的分片.
- 针对Aβ,pTau,神经纤维光 (NfL) 和原IV (COLIV) 的免疫皮组织,分析与线性混合模型的关联.
主要成果:
- 这两种AD表型都显示出门皮皮质体积损失;典型的AD也表现出顶叶损失.
- 总体分析显示了MRI皮质体积和Aβ负载之间的积极关联,以及AD中NFL负载的负面关联.
- 在区域范围内,确定了特定的体积-病理关系,例如在典型的AD中,与Aβ负载相关的上顶顶状状体积,以及在非典型的AD中与NfL负载相关的中前状体积.
结论:
- 在这两种AD表型中,皮层体积受到Aβ和神经轴突损伤的影响,具有相反的效果.
- 在典型和非典型的AD之间存在体积-病理关系的区域特异性差异.
- 这些发现有助于在研究和临床应用中对各种AD队列的MRI数据进行解释.
相关概念视频
Alzheimer's Disease: Overview
317
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
317
Alzheimer's Disease: Treatment
128
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
128
Parkinson's Disease: Overview
310
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
310


